Oncolytics Biotech Inc. (NASDAQ: ONCY) shares slipped 1.9% to $3.57, after it announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel Share volume was 124,000, compared to an all-day average of 305,000